John Marioni elected to EMBO Membership
Senior Group Leader, Dr John Marioni, has been elected a member of the European Molecular Biology Organisation (EMBO) in recognition of his high-quality life science research.
Marioni is one of 64 life scientists that have been elected to EMBO membership this year, joining a community of more than 1,800 leading life scientists.
EMBO Members are actively involved in the organisation. They serve on EMBO Council, Committees, and Advisory Editorial Boards of EMBO Press journals, evaluate applications for EMBO funding, and mentor early-career scientists. Collectively, they can influence the direction of the life sciences in Europe and beyond.
“I am delighted to welcome the new members into our organisation and look forward to working with them,” says EMBO Director Maria Leptin. “An election to the EMBO Membership recognises outstanding achievements in the life sciences. The new members will provide expertise and guidance that will help EMBO to further strengthen its initiatives.”
New members are nominated and elected by the existing EMBO Membership; it is not possible to apply to become a member. One election is held each year. The new EMBO Members will be formally welcomed at the annual EMBO Members’ Meeting between 27 and 29 October 2021.
Related News
See all news-
New immune pathway offers treatment hope for childhood brain tumours
3rd February 2026
A newly discovered immune pathway could lead to gentler treatments for multiple childhood brain cancers, according to new research from our Gilbertson Group published today in Nature Genetics.
Find out more -
Targeting paused cells could improve chemotherapy for lung and ovarian cancers
3rd February 2026
New research published today in Nature Aging by scientists at the University of Cambridge sheds light on why some lung and ovarian cancers stop responding to chemotherapy, and how this resistance might one day be prevented.
Find out more -
Hot flush treatment has anti-breast cancer activity, study finds
5th January 2026
A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast cancer, a new Cambridge-led trial has found.
Find out more